Literature DB >> 10198623

Two new cases of papillary renal cell carcinoma with t(X;1)(p11;q21) in females.

C Pérot1, J Bougaran, L Boccon-Gibod, S Störkel, G Leverger, J van den Akker, J L Taillemite, J Couturier.   

Abstract

Two cases of papillary renal cell carcinoma (RCC) with a karyotype 46,X,t(X;1)(p11.2;q21) in two female patients aged 9 and 29 years are reported. These observations, and the review of the 17 reported cases with a translocation at band Xp11 confirm that this abnormality delineates a clinicopathological entity within the classical papillary RCC, characterized by the early age of occurrence and, probably, distinct histological features. Including these two new female cases, the sex ratio in cases with t(X;1) appears similar to that observed in the other papillary RCC.

Entities:  

Mesh:

Year:  1999        PMID: 10198623     DOI: 10.1016/s0165-4608(98)00181-2

Source DB:  PubMed          Journal:  Cancer Genet Cytogenet        ISSN: 0165-4608


  4 in total

1.  Impairment of MAD2B-PRCC interaction in mitotic checkpoint defective t(X;1)-positive renal cell carcinomas.

Authors:  M A Weterman; J J van Groningen; L Tertoolen; A G van Kessel
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

2.  Papillary renal cell carcinoma. Prognostic value of morphological subtypes in a clinicopathologic study of 43 cases.

Authors:  Yves Allory; Delphine Ouazana; Eric Boucher; Nicolas Thiounn; Annick Vieillefond
Journal:  Virchows Arch       Date:  2003-04-04       Impact factor: 4.064

3.  Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma.

Authors:  Melinda E Sanders; Rosemarie Mick; John E Tomaszewski; Frederic G Barr
Journal:  Am J Pathol       Date:  2002-09       Impact factor: 4.307

4.  Clinicopathological Findings on 28 Cases with XP11.2 Renal Cell Carcinoma.

Authors:  Levente Kuthi; Áron Somorácz; Tamás Micsik; Alex Jenei; Adrienn Hajdu; István Sejben; Dániel Imre; Boglárka Pósfai; Katalin Kóczián; Dávid Semjén; Zoltán Bajory; Janina Kulka; Béla Iványi
Journal:  Pathol Oncol Res       Date:  2020-01-18       Impact factor: 3.201

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.